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Abstract The objective of the study was to compare the
efficacy and safety of frovatriptan and almotriptan in women
with menstrually related migraine (IHS Classification of
Headache disorders) enrolled in a multicenter, randomized,
double-blind, cross-over study. Patients received frovatrip-
tan 2.5 mg or almotriptan 12.5 mg in a randomized
sequence: after treating 3 episodes of migraine in no more
than 3 months with the first treatment, the patient was
switched to the other treatment. 67 of the 96 female patients
of the intention-to-treat population of the main study had
regular menstrual cycles and were thus included in this
subgroup analysis. 77 migraine attacks classified as related to
menses were treated with frovatriptan and 78 with almo-
triptan. Rate of pain relief at 2 and 4 h was 36 and 53 % for
frovatriptan and 41 and 50 % for almotriptan (p = NS
between treatments). Rate of pain free at 2 and 4 h was 19
and 47 % with frovatriptan and 29 and 54 % for almotriptan
(p = NS). At 24 h, 62 % of frovatriptan-treated and 67 % of
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almotriptan-treated patients had pain relief, while 60 versus
67 % were pain free (p = NS). Recurrence at 24 h was
significantly (p \ 0.05) lower with frovatriptan (8 vs. 21 %
almotriptan). This was the case also at 48 h (9 vs. 24 %,
p \ 0.05). Frovatriptan was as effective as almotriptan in the
immediate treatment of menstrually related migraine
attacks. However, it showed a more favorable sustained
effect, as shown by a lower rate of migraine recurrence.
Keywords Migraine  Menstrually related migraine 
Frovatriptan  Almotriptan
Introduction
Female migraineurs frequently experience headaches in
association with their menstrual cycles [1, 2]. These
migraine attacks represent a challenge for both the patient
and the headache specialist as they have been shown to be
particularly difficult to treat and more disabling than
migraines outside of the menstrual period [3].
Triptans are a recommended first-line treatment for
moderate to severe migraine, including menstrual migraine
[2, 4]. Sumatriptan, the first triptan to be marketed, has
been shown to be well tolerated and effective in providing
pain relief in menstrual migraine when administered in the
mild pain phase, and also when used in combination with
analgesics [5–11]. Second generation triptans such as
zolmitriptan [12–14], naratriptan [15], rizatriptan [16–20]
and more recently almotriptan [13, 21–24] and frovatriptan
[25] have also been successfully tested. Most of these drugs
have been found to be effective for treatment or prevention
of the acute attack of menstrual migraine [26, 27].
Efficacy of frovatriptan in the short-term prevention or
acute treatment of menstrual migraine has been demon-
strated in several randomized, double-blind, placebo-con-
trolled or open-label studies [28–34]. In two recently
published retrospective analyses of randomized, double-
blind, cross-over, head-to-head trials, frovatriptan provided
a more sustained pain relief than zolmitriptan and rizatriptan,
with similar pain-free and pain-relief rates at 2 h [35, 36].
The objective of the present study was to add new evi-
dence to the existing body of data through a subgroup
analysis of a double-blind, randomized, cross-over study,
comparing frovatriptan with almotriptan in a broader group
of migraine patients [37].
Methods
Study population
The analysis of the subgroup of women suffering from
menstrual-related migraine population was pre-defined in
the statistical analysis plan and original protocol of the
main study [37]. This condition was defined, according to
the Appendix of the International Headache Society (IHS)
2004 [38] research criteria, as migraine without aura
attacks in a menstruating woman, occurring on day 1 ± 2
(namely days -2 to ?3) of menstruation in at least two out
of three menstrual cycles and additionally at other times of
the cycle. All subjects had to report at least one, but no
more than 6 migraine attacks per month in the 6 months
prior to entering the study.
Exclusion criteria are reported in detail in the main
study publication [37]. Briefly, women were excluded from
the study in case of uncontrolled hypertension, ischemic
heart disease, cardiac arrhythmias, previous stroke or
transient ischemic attack, severe liver or renal impairment
or any other severe or disabling medical condition. History
of alcohol or drug abuse, use of anti-migraine drugs,
including either test medication for treating one of the last
three episodes of migraine, known hypersensitivity to study
drugs, previously demonstrated inadequate response to at
least two triptans or occurrence of other headaches that
have been lasting for more than 6 days, were also consid-
ered as exclusion criteria. Pregnancy and breast-feeding
precluded participation in the study, while women with
childbearing potential but not practicing an effective
method of birth control were to be submitted to a preg-
nancy test, if clinically indicated.
The study was approved by the local institutional review
board of the study centers. Written informed consent was
provided by all patients before study participation.
Study design
This was a multicenter, randomized, double-blind, cross-
over study, including 14 Italian centers (see ‘‘Appendix’’)
[37]. Each patient received frovatriptan 2.5 mg or almo-
triptan 12.5 mg in a randomized sequence: after treating a
maximum of 3 episodes of migraine in no more than
3 months with the first treatment, the patient was switched
to the other treatment and was asked to treat a maximum of
3 episodes of migraine in no more than 3 months with the
second treatment.
Subjects having no migraine episodes during one of the
two observation periods were excluded from the study.
After signing written informed consent, subjects pro-
vided a medical, treatment and migraine history. A physi-
cal and neurological examination and pregnancy test (if
appropriate) were performed. Blood pressure and heart rate
were measured for all subjects. The degree of migraine-
associated disability (MIDAS) questionnaire was also
completed. At the end of the visit a headache diary docu-
menting characteristics of headache pain (including its
relation with menses) and associated symptoms was
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dispensed with study medication to eligible patients. Sub-
jects were instructed to treat a maximum of 3 migraine
episodes within a period of no more than 3 months and
then to come for the second visit. At this second visit, use
of concomitant medications and occurrence of possible
adverse events (obtained from diary card) were checked,
blood pressure and heart rate were recorded, and a preg-
nancy test performed, if deemed necessary. At the end of
the second visit a headache diary documenting character-
istics of headache pain was dispensed with study medica-
tion. The same procedures were carried out at the end of
the second study treatment period or at the early with-
drawal visit.
Patients were instructed to take one dose of study
medication as early as possible after the onset of migraine
attack. If insufficient relief had been obtained after 2 h,
patients were allowed to take a second dose of study
medication, with a maximum daily intake of two doses. In
case of insufficient relief one hour after the intake of the
second dose of the study medication, patients were allowed
to take a rescue medication. Rescue medication could not
include triptans, or contain ergotamine or its derivatives.
The study involved three visits and each patient’s par-
ticipation time in the study was not to exceed 6 months
from randomization.
Randomization was done by blocks of 4. Blindness was
ensured by the overencapsulation technique, i.e., by
inserting study drug tablets in capsules.
Data analysis
The population of this retrospective analysis consisted of
all normally menstruating women randomized to any of the
two treatment sequences, enrolled to receive either of the
study treatments and having treated at least one episode of
menstrual migraine with both medications (intention-to-
treat population).
The following endpoints were evaluated [37]: (a) the
proportion of pain-relief episodes at 2, 4 and 24 h (a
decrease in migraine intensity from severe or moderate to
mild or none at 2, 4 and 24 h); (b) the proportion of pain-
free episodes at 2, 4 and 24 h (absence of migraine epi-
sodes at 2, 4 and 24 h after intake of one dose of study
drug); (c) recurrence within 24 h (episodes pain free at 2 h
and headache of any severity returns within 24 h);
(d) recurrence within 48 h. Changes in headache intensity
(4-point scale from none to severe) from baseline after 2, 4,
24 and 48 h from study drug intake, were also evaluated.
For continuous variables average values and standard
deviation (SD) were calculated. Categorical variables were
summarized by computing the absolute value and the fre-
quency (as percentage). Endpoints were compared between
groups by generalized estimating equation analysis.
Kaplan–Meier curves for cumulative hazard of recurrence
over the 48 h were also drawn. All statistical tests were
performed using a two-sided test with a significance level
of 0.05 (p value).
Results
The main study population consisted of 114 subjects [37],
of which 96 were women. 67 of them treated at least one
episode of menstrual migraine with both medications and
were thus included in the present analysis.
No statistically significant differences were observed for
the main demographic and clinical characteristics of the
patients of the whole study population and of the subgroup
of women with menstrually related migraine (Table 1). The
only exception was a significantly (p \ 0.05) wider use of
triptans in the previous 3 months in the women with
menstrually related migraine.
A total of 77 attacks (24 % of all attacks) classified as
menstrually related migraine were treated with frovatriptan
and 78 (24 %) with almotriptan.
As indicated in Table 2, the proportion of pain-relief
episodes was similar (p = NS) between frovatriptan and
almotriptan at 2 h (36 vs. 41 %), 4 h (53 vs. 50 %) and
24 h (62 vs. 67 %). Also the rate of pain-free episodes at 2,
4 and 24 h did not differ between the two treatment groups
(19, 47 and 60 % frovatriptan vs. 29, 54 and 67 % almo-
triptan; p = NS for both) (Table 2).
The rate of migraine recurrence after 24 h was lower
(p \ 0.05) with frovatriptan than with almotriptan (8 vs.
21 %). This was the case also for recurrences at 48 h (9 %
frovatriptan vs. 24 % almotriptan, p \ 0.05). Also, the
cumulative hazard of recurrence during the follow-up was
significantly (p \ 0.05) lower with frovatriptan, as dis-
played in Fig. 1.
During the 48-h observation period, migraine intensity
was progressively reduced by both drugs, with a statisti-
cally significant larger reduction (p \ 0.05) with frova-
triptan than with almotriptan at 24 and 48 h (Fig. 2).
Discussion
In the present subgroup analysis of a double-blind, ran-
domized, cross-over study [37], acute treatment of men-
strually related migraine attacks with frovatriptan and
almotriptan was associated with similar proportions of
pain-relief and of pain-free episodes at 2, 4 and 24 h
between the two drugs. However, frovatriptan showed
significantly lower rates of headache recurrence over the 24
and 48 h than almotriptan. These results seem to indicate a
more prolonged beneficial effect of frovatriptan compared
J Headache Pain (2012) 13:401–406 403
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to almotriptan, probably because of the different pharma-
cokinetics of the two drugs. Frovatriptan has a longer half-
life than almotriptan (25–26 h vs. 3–4 h), which probably
explains why frovatriptan has been reported to have a
lower incidence of migraine recurrence than almotriptan
[39–42]. Differences between the two drugs in this regard
might be further enhanced in the subgroup of women with
menstrually related migraine, who are known to suffer
from a more disabling form of migraine as compared to
non-menstrual migraineurs [1–3].
Results of our study corroborate those of previous ran-
domized, placebo-controlled or open-label studies, which
proved the efficacy of frovatriptan in the short-term pre-
vention [28–32] or acute treatment of menstrual migraine
[33–36]. Our results also provide more evidence and con-
firm results of previous almotriptan-based trials. In a
retrospective analysis of a multicenter, multinational, ran-
domized, double-blind parallel clinical trial, including 136
women treating a menstrual migraine attack with almo-
triptan, 68 % of subjects had obtained pain relief and 45 %
were pain free at 2 h, while recurrence rates between 2 and
24 h after dosing were 33 % [13]. In another post hoc
analysis of a multicenter, double-blind, parallel group,
Table 1 Demographic and
clinical baseline data of the 114
patients of the main study [37]
and of the subgroup of 67
women with menstrually related
migraine
Data are shown as mean (±SD),
or absolute (n) and relative
frequency (%)
a Numbers refer to number and
frequency of attacks as respect
to overall number of attacks
Main study
(n = 114)
Menstruating
women (n = 67)
p
Age (years, means ± SD) 40 ± 10 37 ± 8 NS
Height (cm, means ± SD) 165 ± 6 164 ± 6 NS
Weight (kg, means ± SD) 65 ± 12 62 ± 10 NS
Age at onset of migraine (years, means ± SD) 18 ± 8 17 ± 7 NS
Migraine attack duration [2 days (n, %) 29 (25) 16 (24) NS
MIDAS score (means ± SD) 23 ± 16 23 ± 16 NS
No use of triptans in the previous 3 months (n, %) 93 (82) 46 (69) \0.05
Moderate or severe attacks (n, %)a 532 (80) 133 (86) NS
Patients with at least one moderate or severe attack (n, %) 111 (97) 64 (96) NS
Table 2 Main study endpoints in the two study treatment groups
Frovatriptan Almotriptan p
Pain-relief episodes at 2 h 28 (36) 32 (41) NS
Pain-free episodes at 2 h 15 (19) 23 (29) NS
Pain-relief episodes at 4 h 41 (53) 38 (50) NS
Pain-free episodes at 4 h 36 (47) 42 (54) NS
Pain-relief episodes at 24 h 48 (62) 53 (67) NS
Pain-free episodes at 24 h 46 (60) 52 (67) NS
Recurrent episodes at 24 h 6 (8) 16 (21) \0.05
Recurrent episodes at 48 h 7 (9) 19 (24) \0.05
Data are reported as absolute (n) and relative (%) frequency. p refers
to the statistical significance of the difference between the two study
drugs
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Fig. 1 Cumulative hazard of recurrence over the 24 h during
treatment with frovatriptan (continuous line) or almotriptan (dashed
line) in the 67 women with menstrually related migraine included in
this analysis. The p value refers to the statistical significance of the
between-treatment difference
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Fig. 2 Changes in migraine intensity from baseline during treatment
with frovatriptan (continuous line) or almotriptan (dashed line) in the
67 women with menstrually related migraine included in this analysis.
The asterisks refer to the statistical significance of the between-
treatment difference (*p \ 0.05)
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placebo-controlled trial almotriptan treatment in 97 women
with menstrually related migraine resulted in 2 h pain
relief, 2 h pain free and sustained pain-free rates of 77, 35
and 23 %, respectively [21]. Finally, in a recent random-
ized, double-blind, placebo-controlled cross-over study,
including 74 premenopausal women with menstrually
related migraine, almotriptan was associated with a sig-
nificantly higher percentage of patients free of pain at 2 h
compared with placebo (48 vs. 26 %). In this study, overall
36 % of patients were found to be sustained pain free with
almotriptan versus 17 % with placebo [22]. The propor-
tions achieved for study endpoints in almotriptan-treated
patients in the trials cited above were slightly higher than
those observed in our study.
Our study was the first directly comparing the efficacy
of frovatriptan and almotriptan for the acute treatments for
menstrually related migraine. In previous publications,
frovatriptan showed pain-relief and pain-free rates at 2 and
24 h similar to those of rizatriptan and zolmitriptan, but
significantly lower rates of recurrences at 24 h (15 vs.
22 % zolmitriptan and 10 vs. 32 % rizatriptan) [35, 36]. In
another head-to-head double-blind, randomized trial com-
paring almotriptan with zolmitriptan, no significant dif-
ferences between the two treatments were found, with
similar pain-relief rates at 2 h (68 vs. 69 %), similar pain-
free rates at 2 h (45 vs. 41 %) and similar recurrences at
2–24 h (33 vs. 35 %) [13].
In conclusion, results of the present analysis of data
from a multicenter, randomized, double-blind, head-to-
head, cross-over study suggest that frovatriptan and
almotriptan are similarly effective in the immediate
treatment of acute attack of menstrually related migraine.
However, since frovatriptan seems to be superior to al-
motriptan in providing sustained relief from pain, this
may suggest the use of the former in those patients with
long-duration or high frequency of recurrence of migraine
attacks. In the light of our results, we would indicate the
use of frovatriptan in women with menstrual migraine,
but with the caution of avoiding drug overuse or misuse,
e.g. by limiting its use to more severe perimenstrual
attacks. This will prevent occurrence of adverse events
and progression and chronification of migraine, a risk
which is directly related to the number of days with
symptomatic drug intake.
We acknowledge that the retrospective nature of our
analysis makes subsequent double-blind, randomized,
prospective, large clinical trials mandatory to support our
data.
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